Skip to content

Vor Biopharma VOR Net Change in Cash

Net Change in Cash at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.98B-86.2%
Amgen logo
AmgenAMGN
$2.91B+192%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$417.1M+268%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$576.58M+4,649%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$13.25M-109%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
-$4.09M+54.1%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,513%
Enterprise value$617.68M+5,639%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's net change in cash?
Vor Biopharma (VOR) reported net change in cash of -$226.61M in Q1 2026.
How has Vor Biopharma's net change in cash changed year-over-year?
Vor Biopharma's net change in cash decreased by 610.3% year-over-year, from -$31.9M to -$226.61M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.